The global market for Anti-obesity Medicine was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Anti-obesity Medicine, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Anti-obesity Medicine by region & country, by Type, and by Application.

The Anti-obesity Medicine market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-obesity Medicine.

Market Segmentation

Scope of Anti-obesity Medicine - Market Report

Report Metric	Details
Report Name	Anti-obesity Medicine - Market
CAGR	5%
Segment by Type:	Prescription Drugs OTC Drugs
Segment by Application	Men Women
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Alizyme, Amylin Pharmaceuticals, Arena Pharmaceuticals, Boehringer Ingelheim, Eisai, GlaxoSmithKline, Orexigen Therapeutics, Vivus, Pfizer, Roche, Merck, Novo Nordisk
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Anti-obesity Medicine manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Anti-obesity Medicine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Anti-obesity Medicine in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

Who are the main players in the Anti-obesity Medicine - Market report?

Ans: The main players in the Anti-obesity Medicine - Market are Alizyme, Amylin Pharmaceuticals, Arena Pharmaceuticals, Boehringer Ingelheim, Eisai, GlaxoSmithKline, Orexigen Therapeutics, Vivus, Pfizer, Roche, Merck, Novo Nordisk

What are the Application segmentation covered in the Anti-obesity Medicine - Market report?

Ans: The Applications covered in the Anti-obesity Medicine - Market report are Men, Women

What are the Type segmentation covered in the Anti-obesity Medicine - Market report?

Ans: The Types covered in the Anti-obesity Medicine - Market report are Prescription Drugs, OTC Drugs

1 Market Overview

1.1 Anti-obesity Medicine Product Introduction

1.2 Global Anti-obesity Medicine Market Size Forecast

1.3 Anti-obesity Medicine Market Trends & Drivers

1.3.1 Anti-obesity Medicine Industry Trends

1.3.2 Anti-obesity Medicine Market Drivers & Opportunity

1.3.3 Anti-obesity Medicine Market Challenges

1.3.4 Anti-obesity Medicine Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Anti-obesity Medicine Players Revenue Ranking (2023)

2.2 Global Anti-obesity Medicine Revenue by Company (2019-2024)

2.3 Key Companies Anti-obesity Medicine Manufacturing Base Distribution and Headquarters

2.4 Key Companies Anti-obesity Medicine Product Offered

2.5 Key Companies Time to Begin Mass Production of Anti-obesity Medicine

2.6 Anti-obesity Medicine Market Competitive Analysis

2.6.1 Anti-obesity Medicine Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by Anti-obesity Medicine Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-obesity Medicine as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Prescription Drugs

3.1.2 OTC Drugs

3.2 Global Anti-obesity Medicine Sales Value by Type

3.2.1 Global Anti-obesity Medicine Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Anti-obesity Medicine Sales Value, by Type (2019-2030)

3.2.3 Global Anti-obesity Medicine Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Men

4.1.2 Women

4.2 Global Anti-obesity Medicine Sales Value by Application

4.2.1 Global Anti-obesity Medicine Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Anti-obesity Medicine Sales Value, by Application (2019-2030)

4.2.3 Global Anti-obesity Medicine Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global Anti-obesity Medicine Sales Value by Region

5.1.1 Global Anti-obesity Medicine Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Anti-obesity Medicine Sales Value by Region (2019-2024)

5.1.3 Global Anti-obesity Medicine Sales Value by Region (2025-2030)

5.1.4 Global Anti-obesity Medicine Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America Anti-obesity Medicine Sales Value, 2019-2030

5.2.2 North America Anti-obesity Medicine Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe Anti-obesity Medicine Sales Value, 2019-2030

5.3.2 Europe Anti-obesity Medicine Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific Anti-obesity Medicine Sales Value, 2019-2030

5.4.2 Asia Pacific Anti-obesity Medicine Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America Anti-obesity Medicine Sales Value, 2019-2030

5.5.2 South America Anti-obesity Medicine Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa Anti-obesity Medicine Sales Value, 2019-2030

5.6.2 Middle East & Africa Anti-obesity Medicine Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Anti-obesity Medicine Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Anti-obesity Medicine Sales Value

6.3 United States

6.3.1 United States Anti-obesity Medicine Sales Value, 2019-2030

6.3.2 United States Anti-obesity Medicine Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Anti-obesity Medicine Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Anti-obesity Medicine Sales Value, 2019-2030

6.4.2 Europe Anti-obesity Medicine Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Anti-obesity Medicine Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Anti-obesity Medicine Sales Value, 2019-2030

6.5.2 China Anti-obesity Medicine Sales Value by Type (%), 2023 VS 2030

6.5.3 China Anti-obesity Medicine Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Anti-obesity Medicine Sales Value, 2019-2030

6.6.2 Japan Anti-obesity Medicine Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Anti-obesity Medicine Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Anti-obesity Medicine Sales Value, 2019-2030

6.7.2 South Korea Anti-obesity Medicine Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Anti-obesity Medicine Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Anti-obesity Medicine Sales Value, 2019-2030

6.8.2 Southeast Asia Anti-obesity Medicine Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Anti-obesity Medicine Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Anti-obesity Medicine Sales Value, 2019-2030

6.9.2 India Anti-obesity Medicine Sales Value by Type (%), 2023 VS 2030

6.9.3 India Anti-obesity Medicine Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Alizyme

7.1.1 Alizyme Profile

7.1.2 Alizyme Main Business

7.1.3 Alizyme Anti-obesity Medicine Products, Services and Solutions

7.1.4 Alizyme Anti-obesity Medicine Revenue (US$ Million) & (2019-2024)

7.1.5 Alizyme Recent Developments

7.2 Amylin Pharmaceuticals

7.2.1 Amylin Pharmaceuticals Profile

7.2.2 Amylin Pharmaceuticals Main Business

7.2.3 Amylin Pharmaceuticals Anti-obesity Medicine Products, Services and Solutions

7.2.4 Amylin Pharmaceuticals Anti-obesity Medicine Revenue (US$ Million) & (2019-2024)

7.2.5 Amylin Pharmaceuticals Recent Developments

7.3 Arena Pharmaceuticals

7.3.1 Arena Pharmaceuticals Profile

7.3.2 Arena Pharmaceuticals Main Business

7.3.3 Arena Pharmaceuticals Anti-obesity Medicine Products, Services and Solutions

7.3.4 Arena Pharmaceuticals Anti-obesity Medicine Revenue (US$ Million) & (2019-2024)

7.3.5 Boehringer Ingelheim Recent Developments

7.4 Boehringer Ingelheim

7.4.1 Boehringer Ingelheim Profile

7.4.2 Boehringer Ingelheim Main Business

7.4.3 Boehringer Ingelheim Anti-obesity Medicine Products, Services and Solutions

7.4.4 Boehringer Ingelheim Anti-obesity Medicine Revenue (US$ Million) & (2019-2024)

7.4.5 Boehringer Ingelheim Recent Developments

7.5 Eisai

7.5.1 Eisai Profile

7.5.2 Eisai Main Business

7.5.3 Eisai Anti-obesity Medicine Products, Services and Solutions

7.5.4 Eisai Anti-obesity Medicine Revenue (US$ Million) & (2019-2024)

7.5.5 Eisai Recent Developments

7.6 GlaxoSmithKline

7.6.1 GlaxoSmithKline Profile

7.6.2 GlaxoSmithKline Main Business

7.6.3 GlaxoSmithKline Anti-obesity Medicine Products, Services and Solutions

7.6.4 GlaxoSmithKline Anti-obesity Medicine Revenue (US$ Million) & (2019-2024)

7.6.5 GlaxoSmithKline Recent Developments

7.7 Orexigen Therapeutics

7.7.1 Orexigen Therapeutics Profile

7.7.2 Orexigen Therapeutics Main Business

7.7.3 Orexigen Therapeutics Anti-obesity Medicine Products, Services and Solutions

7.7.4 Orexigen Therapeutics Anti-obesity Medicine Revenue (US$ Million) & (2019-2024)

7.7.5 Orexigen Therapeutics Recent Developments

7.8 Vivus

7.8.1 Vivus Profile

7.8.2 Vivus Main Business

7.8.3 Vivus Anti-obesity Medicine Products, Services and Solutions

7.8.4 Vivus Anti-obesity Medicine Revenue (US$ Million) & (2019-2024)

7.8.5 Vivus Recent Developments

7.9 Pfizer

7.9.1 Pfizer Profile

7.9.2 Pfizer Main Business

7.9.3 Pfizer Anti-obesity Medicine Products, Services and Solutions

7.9.4 Pfizer Anti-obesity Medicine Revenue (US$ Million) & (2019-2024)

7.9.5 Pfizer Recent Developments

7.10 Roche

7.10.1 Roche Profile

7.10.2 Roche Main Business

7.10.3 Roche Anti-obesity Medicine Products, Services and Solutions

7.10.4 Roche Anti-obesity Medicine Revenue (US$ Million) & (2019-2024)

7.10.5 Roche Recent Developments

7.11 Merck

7.11.1 Merck Profile

7.11.2 Merck Main Business

7.11.3 Merck Anti-obesity Medicine Products, Services and Solutions

7.11.4 Merck Anti-obesity Medicine Revenue (US$ Million) & (2019-2024)

7.11.5 Merck Recent Developments

7.12 Novo Nordisk

7.12.1 Novo Nordisk Profile

7.12.2 Novo Nordisk Main Business

7.12.3 Novo Nordisk Anti-obesity Medicine Products, Services and Solutions

7.12.4 Novo Nordisk Anti-obesity Medicine Revenue (US$ Million) & (2019-2024)

7.12.5 Novo Nordisk Recent Developments

8 Industry Chain Analysis

8.1 Anti-obesity Medicine Industrial Chain

8.2 Anti-obesity Medicine Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Anti-obesity Medicine Sales Model

8.5.2 Sales Channel

8.5.3 Anti-obesity Medicine Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Alizyme

Amylin Pharmaceuticals

Arena Pharmaceuticals

Boehringer Ingelheim

Eisai Co Ltd

GlaxoSmithKline PLC

Orexigen Therapeutics

List of Tables

Table 1. Anti-obesity Medicine Market Trends

Table 2. Anti-obesity Medicine Market Drivers & Opportunity

Table 3. Anti-obesity Medicine Market Challenges

Table 4. Anti-obesity Medicine Market Restraints

Table 5. Global Anti-obesity Medicine Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Anti-obesity Medicine Revenue Market Share by Company (2019-2024)

Table 7. Key Companies Anti-obesity Medicine Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Anti-obesity Medicine Product Type

Table 9. Key Companies Time to Begin Mass Production of Anti-obesity Medicine

Table 10. Global Anti-obesity Medicine Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-obesity Medicine as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Anti-obesity Medicine Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global Anti-obesity Medicine Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global Anti-obesity Medicine Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global Anti-obesity Medicine Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global Anti-obesity Medicine Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global Anti-obesity Medicine Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global Anti-obesity Medicine Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global Anti-obesity Medicine Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global Anti-obesity Medicine Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global Anti-obesity Medicine Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global Anti-obesity Medicine Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global Anti-obesity Medicine Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global Anti-obesity Medicine Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global Anti-obesity Medicine Sales Value by Region (2019-2024) & (%)

Table 27. Global Anti-obesity Medicine Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions Anti-obesity Medicine Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions Anti-obesity Medicine Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions Anti-obesity Medicine Sales Value, (2025-2030) & (US$ Million)

Table 31. Alizyme Basic Information List

Table 32. Alizyme Description and Business Overview

Table 33. Alizyme Anti-obesity Medicine Products, Services and Solutions

Table 34. Revenue (US$ Million) in Anti-obesity Medicine Business of Alizyme (2019-2024)

Table 35. Alizyme Recent Developments

Table 36. Amylin Pharmaceuticals Basic Information List

Table 37. Amylin Pharmaceuticals Description and Business Overview

Table 38. Amylin Pharmaceuticals Anti-obesity Medicine Products, Services and Solutions

Table 39. Revenue (US$ Million) in Anti-obesity Medicine Business of Amylin Pharmaceuticals (2019-2024)

Table 40. Amylin Pharmaceuticals Recent Developments

Table 41. Arena Pharmaceuticals Basic Information List

Table 42. Arena Pharmaceuticals Description and Business Overview

Table 43. Arena Pharmaceuticals Anti-obesity Medicine Products, Services and Solutions

Table 44. Revenue (US$ Million) in Anti-obesity Medicine Business of Arena Pharmaceuticals (2019-2024)

Table 45. Arena Pharmaceuticals Recent Developments

Table 46. Boehringer Ingelheim Basic Information List

Table 47. Boehringer Ingelheim Description and Business Overview

Table 48. Boehringer Ingelheim Anti-obesity Medicine Products, Services and Solutions

Table 49. Revenue (US$ Million) in Anti-obesity Medicine Business of Boehringer Ingelheim (2019-2024)

Table 50. Boehringer Ingelheim Recent Developments

Table 51. Eisai Basic Information List

Table 52. Eisai Description and Business Overview

Table 53. Eisai Anti-obesity Medicine Products, Services and Solutions

Table 54. Revenue (US$ Million) in Anti-obesity Medicine Business of Eisai (2019-2024)

Table 55. Eisai Recent Developments

Table 56. GlaxoSmithKline Basic Information List

Table 57. GlaxoSmithKline Description and Business Overview

Table 58. GlaxoSmithKline Anti-obesity Medicine Products, Services and Solutions

Table 59. Revenue (US$ Million) in Anti-obesity Medicine Business of GlaxoSmithKline (2019-2024)

Table 60. GlaxoSmithKline Recent Developments

Table 61. Orexigen Therapeutics Basic Information List

Table 62. Orexigen Therapeutics Description and Business Overview

Table 63. Orexigen Therapeutics Anti-obesity Medicine Products, Services and Solutions

Table 64. Revenue (US$ Million) in Anti-obesity Medicine Business of Orexigen Therapeutics (2019-2024)

Table 65. Orexigen Therapeutics Recent Developments

Table 66. Vivus Basic Information List

Table 67. Vivus Description and Business Overview

Table 68. Vivus Anti-obesity Medicine Products, Services and Solutions

Table 69. Revenue (US$ Million) in Anti-obesity Medicine Business of Vivus (2019-2024)

Table 70. Vivus Recent Developments

Table 71. Pfizer Basic Information List

Table 72. Pfizer Description and Business Overview

Table 73. Pfizer Anti-obesity Medicine Products, Services and Solutions

Table 74. Revenue (US$ Million) in Anti-obesity Medicine Business of Pfizer (2019-2024)

Table 75. Pfizer Recent Developments

Table 76. Roche Basic Information List

Table 77. Roche Description and Business Overview

Table 78. Roche Anti-obesity Medicine Products, Services and Solutions

Table 79. Revenue (US$ Million) in Anti-obesity Medicine Business of Roche (2019-2024)

Table 80. Roche Recent Developments

Table 81. Merck Basic Information List

Table 82. Merck Description and Business Overview

Table 83. Merck Anti-obesity Medicine Products, Services and Solutions

Table 84. Revenue (US$ Million) in Anti-obesity Medicine Business of Merck (2019-2024)

Table 85. Merck Recent Developments

Table 86. Novo Nordisk Basic Information List

Table 87. Novo Nordisk Description and Business Overview

Table 88. Novo Nordisk Anti-obesity Medicine Products, Services and Solutions

Table 89. Revenue (US$ Million) in Anti-obesity Medicine Business of Novo Nordisk (2019-2024)

Table 90. Novo Nordisk Recent Developments

Table 91. Key Raw Materials Lists

Table 92. Raw Materials Key Suppliers Lists

Table 93. Anti-obesity Medicine Downstream Customers

Table 94. Anti-obesity Medicine Distributors List

Table 95. Research Programs/Design for This Report

Table 96. Key Data Information from Secondary Sources

Table 97. Key Data Information from Primary Sources

Table 98. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Anti-obesity Medicine Product Picture

Figure 2. Global Anti-obesity Medicine Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Anti-obesity Medicine Sales Value (2019-2030) & (US$ Million)

Figure 4. Anti-obesity Medicine Report Years Considered

Figure 5. Global Anti-obesity Medicine Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Anti-obesity Medicine Revenue in 2023

Figure 7. Anti-obesity Medicine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. Prescription Drugs Picture

Figure 9. OTC Drugs Picture

Figure 10. Global Anti-obesity Medicine Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 11. Global Anti-obesity Medicine Sales Value Market Share by Type, 2023 & 2030

Figure 12. Product Picture of Men

Figure 13. Product Picture of Women

Figure 14. Global Anti-obesity Medicine Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 15. Global Anti-obesity Medicine Sales Value Market Share by Application, 2023 & 2030

Figure 16. North America Anti-obesity Medicine Sales Value (2019-2030) & (US$ Million)

Figure 17. North America Anti-obesity Medicine Sales Value by Country (%), 2023 VS 2030

Figure 18. Europe Anti-obesity Medicine Sales Value (2019-2030) & (US$ Million)

Figure 19. Europe Anti-obesity Medicine Sales Value by Country (%), 2023 VS 2030

Figure 20. Asia Pacific Anti-obesity Medicine Sales Value (2019-2030) & (US$ Million)

Figure 21. Asia Pacific Anti-obesity Medicine Sales Value by Country (%), 2023 VS 2030

Figure 22. South America Anti-obesity Medicine Sales Value (2019-2030) & (US$ Million)

Figure 23. South America Anti-obesity Medicine Sales Value by Country (%), 2023 VS 2030

Figure 24. Middle East & Africa Anti-obesity Medicine Sales Value (2019-2030) & (US$ Million)

Figure 25. Middle East & Africa Anti-obesity Medicine Sales Value by Country (%), 2023 VS 2030

Figure 26. Key Countries/Regions Anti-obesity Medicine Sales Value (%), (2019-2030)

Figure 27. United States Anti-obesity Medicine Sales Value, (2019-2030) & (US$ Million)

Figure 28. United States Anti-obesity Medicine Sales Value by Type (%), 2023 VS 2030

Figure 29. United States Anti-obesity Medicine Sales Value by Application (%), 2023 VS 2030

Figure 30. Europe Anti-obesity Medicine Sales Value, (2019-2030) & (US$ Million)

Figure 31. Europe Anti-obesity Medicine Sales Value by Type (%), 2023 VS 2030

Figure 32. Europe Anti-obesity Medicine Sales Value by Application (%), 2023 VS 2030

Figure 33. China Anti-obesity Medicine Sales Value, (2019-2030) & (US$ Million)

Figure 34. China Anti-obesity Medicine Sales Value by Type (%), 2023 VS 2030

Figure 35. China Anti-obesity Medicine Sales Value by Application (%), 2023 VS 2030

Figure 36. Japan Anti-obesity Medicine Sales Value, (2019-2030) & (US$ Million)

Figure 37. Japan Anti-obesity Medicine Sales Value by Type (%), 2023 VS 2030

Figure 38. Japan Anti-obesity Medicine Sales Value by Application (%), 2023 VS 2030

Figure 39. South Korea Anti-obesity Medicine Sales Value, (2019-2030) & (US$ Million)

Figure 40. South Korea Anti-obesity Medicine Sales Value by Type (%), 2023 VS 2030

Figure 41. South Korea Anti-obesity Medicine Sales Value by Application (%), 2023 VS 2030

Figure 42. Southeast Asia Anti-obesity Medicine Sales Value, (2019-2030) & (US$ Million)

Figure 43. Southeast Asia Anti-obesity Medicine Sales Value by Type (%), 2023 VS 2030

Figure 44. Southeast Asia Anti-obesity Medicine Sales Value by Application (%), 2023 VS 2030

Figure 45. India Anti-obesity Medicine Sales Value, (2019-2030) & (US$ Million)

Figure 46. India Anti-obesity Medicine Sales Value by Type (%), 2023 VS 2030

Figure 47. India Anti-obesity Medicine Sales Value by Application (%), 2023 VS 2030

Figure 48. Anti-obesity Medicine Industrial Chain

Figure 49. Anti-obesity Medicine Manufacturing Cost Structure

Figure 50. Channels of Distribution (Direct Sales, and Distribution)

Figure 51. Bottom-up and Top-down Approaches for This Report

Figure 52. Data Triangulation

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions